Xeris (XERS) CMO receives 121K RSUs and 162K options in equity grant
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Xeris Biopharma Holdings Chief Medical Officer Nguyen Anh Tu reported new equity awards. On January 30, 2026, he received 121,293 shares of common stock through a restricted stock unit grant and 162,162 stock options with a $7.36 exercise price.
The restricted stock units and stock options each vest in equal annual installments over three years, conditioned on continued employment or service. Following the grant, he directly holds 424,323 shares of common stock and 162,162 options, plus indirect holdings of common stock through an IRA and a children's IRA, for which he disclaims beneficial ownership beyond his economic interest.
Positive
- None.
Negative
- None.
Insider Trade Summary
4 transactions reported
Mixed
4 txns
Insider
Nguyen Anh Tu
Role
See Remarks
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 162,162 | $0.00 | -- |
| Grant/Award | Common Stock | 121,293 | $0.00 | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 162,162 shares (Direct);
Common Stock — 424,323 shares (Direct);
Common Stock — 3,710 shares (Indirect, By IRA)
Footnotes (1)
- These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan (the "Plan"). Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years, subject to continued employment through such vesting date. Includes 3,030 shares acquired on December 31, 2025 under the issuer's 2018 Employee Stock Purchase Plan, as amended. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. These stock options were acquired pursuant to a grant under the Plan. These stock options shall vest in equal annual installments over three years, subject to continued service through such vesting date.
FAQ
What insider transaction did XERS report for Nguyen Anh Tu?
Xeris Biopharma’s Chief Medical Officer Nguyen Anh Tu reported receiving new equity awards. He was granted 121,293 restricted stock units and 162,162 stock options on January 30, 2026, both vesting over three years, reflecting part of his long-term incentive compensation package.
How many XERS restricted stock units were granted to Nguyen Anh Tu?
Nguyen Anh Tu received 121,293 restricted stock units in Xeris Biopharma common stock. Each unit represents a right to one share and vests in equal annual installments over three years, contingent on his continued employment with the company during the vesting period.
What are the terms of the XERS stock options granted to Nguyen Anh Tu?
He was granted 162,162 stock options with a $7.36 exercise price. These options vest in equal annual installments over three years, subject to continued service, and are exercisable for Xeris Biopharma common stock until their stated expiration date in 2036.
What XERS equity plans were used for Nguyen Anh Tu’s awards?
The restricted stock units and stock options were issued under Xeris Biopharma’s 2018 Stock Option and Incentive Plan. Additionally, his total shares include 3,030 shares acquired on December 31, 2025 under the company’s 2018 Employee Stock Purchase Plan, as amended.